Superior PFS with SARCLISA + Pd vs Pd alone1See the Full Efficacy Data
75-minute infusion time after the second infusion (in the absence of IRRs)1View Dosing
Resources to help eligible patients access SARCLISALearn About CareASSIST
*ORR included sCR, CR, VGPR, and PR. sCR, CR, VGPR, and PR were evaluated by an IRC using the IMWG response criteria. CR=complete response; IMWG=International Myeloma Working Group; IRC=independent response committee; IRR=infusion-related reaction; ORR=overall response rate; PFS=progression-free survival; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Isatuximab-irfc (SARCLISA) is the only mAb in combination with pomalidomide and dexamethasone included as an NCCN Guidelines® Category 1 recommended regimen for previously treated multiple myeloma.2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
mAb=monoclonal antibody; NCCN=National Comprehensive Cancer Network.